Drug General Information
Drug ID	D06KTJ
Former ID	DIB006257
Drug Name	TAK-659
Indication	Hematological malignancies [ICD9: 200-209; ICD10:C81-C86]		Phase 1/2	[525038]
Company	Millennium pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Tyrosine-protein kinase SYK	Target Info	Inhibitor	[549697]
KEGG Pathway	NF-kappa B signaling pathway
	PI3K-Akt signaling pathway
	Osteoclast differentiation
	Platelet activation
	Natural killer cell mediated cytotoxicity
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Fc gamma R-mediated phagocytosis
	Tuberculosis
	Epstein-Barr virus infection
	Viral carcinogenesis
PANTHER Pathway	B cell activation
Pathway Interaction Database	Fc-epsilon receptor I signaling in mast cells
	BCR signaling pathway
	GMCSF-mediated signaling events
	Atypical NF-kappaB pathway
	Osteopontin-mediated events
	FAS (CD95) signaling pathway
	Thromboxane A2 receptor signaling
	IL2-mediated signaling events
	Class I PI3K signaling events
	Alpha-synuclein signaling
PathWhiz Pathway	Fc Epsilon Receptor I Signaling in Mast Cells
Reactome	GPVI-mediated activation cascade
	FCGR activation
	Regulation of actin dynamics for phagocytic cup formation
	Role of phospholipids in phagocytosis
	DAP12 signaling
	Fc epsilon receptor (FCERI) signaling
	Role of LAT2/NTAL/LAB on calcium mobilization
	FCERI mediated MAPK activation
	FCERI mediated Ca+2 mobilization
	Integrin alphaIIb beta3 signaling
	Interleukin-2 signaling
	CLEC7A (Dectin-1) signaling
	Dectin-2 family
	Regulation of signaling by CBL
	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways	IL-2 Signaling Pathway
	IL-3 Signaling Pathway
	Fc epsilon receptor (FCERI) signaling
	Signaling by the B Cell Receptor (BCR)
	Interleukin-2 signaling
	Fcgamma receptor (FCGR) dependent phagocytosis
	DAP12 interactions
	B Cell Receptor Signaling Pathway
	RANKL/RANK Signaling Pathway
	Integrin alphaIIb beta3 signaling
	GPVI-mediated activation cascade
	Regulation of toll-like receptor signaling pathway
	IL-5 Signaling Pathway
References
Ref 525038	ClinicalTrials.gov (NCT02323113) Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
Ref 549697	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.